Bloomberg (1 June 2025) reported that drugs such as Bristol Myers Squibb's Opdivo, AstraZeneca's Imfinzi, and Roche's Tecentriq show significant promise in preventing recurrence and improving long-term survival in operable tumours. These drugs were previously used as life-extending treatments for advanced diseases.
“The latest findings, presented at the prestigious American Society of Clinical Oncology (ASCO) meeting in Chicago, highlight a crucial shift in cancer treatment strategy.
“This paradigm shift offers renewed hope for patients battling stubborn cancers, particularly those at high risk of relapse after surgery.”
“These advancements underscore a pivotal moment in oncology, where the strategic early application of immunotherapies is poised to fundamentally redefine treatment paradigms and significantly improve outcomes for countless cancer patients worldwide.”